Loss of CDKN2A remodels Golgi morphology to create a lipid peroxidation vulnerability
Loss of the tumor suppressor CDKN2A/p16 occurs in ~50% of human cancers, yet no therapies specifically target tumors with complete loss or reduced CDKN2A/p
Loss of the tumor suppressor CDKN2A/p16 occurs in ~50% of human cancers, yet no therapies specifically target tumors with complete loss or reduced CDKN2A/p